First human tests of new hepatitis b vaccines show early safety data

NCT ID NCT05770895

Summary

This early-stage study tested the safety of two experimental therapeutic vaccines (GS-2829 and GS-6779) designed to treat chronic hepatitis B. The study involved 83 participants, including both healthy volunteers and people with stable, well-controlled hepatitis B infection. The main goal was to check for side effects and see if the vaccines could stimulate an immune response against the hepatitis B virus in infected participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833, Taiwan

  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital

    Taoyuan, 33305, Taiwan

  • Chia-Yi Christian Hospital

    Chiayi City, 60002, Taiwan

  • E-DA Hospital

    Kaohsiung City, 82445, Taiwan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, 807, Taiwan

  • National Cheng Kung University Hospital

    Tainan, 7428, Taiwan

  • National Taiwan University Hospital

    Taipei, 100229, Taiwan

  • New Zealand Clinical Research (NZCR)

    Auckland, 1010, New Zealand

  • St. Martin De Porres Hospital

    Chiayi City, 600, Taiwan

Conditions

Explore the condition pages connected to this study.